Azitra Posts Third-Quarter Loss of $0.29 Per Share, Flags Liquidity Pressure
Key Facts
Azitra reported basic and diluted loss per share of $0.29 for the three months ended September 30, 2026, compared with a loss of $6.71 per share in the same period of 2025, according to a filing with the U.S. Securities and Exchange Commission. Net loss attributable to common shareholders was $2,949,779, versus $2,764,528 a year earlier. The figures put quarterly performance in the context of an early-stage clinical biopharmaceutical company that continues to report operating losses. The company said it had not begun revenue-generating operations and had a limited operating history. In the filing, Azitra described itself as a clinical-stage biopharmaceutical company founded in January 2014.
Research and development expenses rose to $1,290,644 in the third quarter from $1,180,078 in the corresponding quarter of 2025. According to the filing, these costs include salaries and benefits for research employees, expenses for contract research organizations and consultants, and laboratory supplies, net of development-related tax credits. For the nine months ended September 30, research and development expenses totaled $4,202,738, compared with $3,832,017 in the same period a year earlier. General and administrative expenses also rose during the quarter, to $1,614,814 from $1,588,406. The increase in both research and administrative expenses came alongside a wider quarterly loss compared with the previous year.
For the first nine months of 2026, the company reported a net loss of $10,224,679, compared with $8,721,866 in the corresponding period of 2025. Operations used $8,670,334 in cash during the period, compared with $8,331,514 a year earlier. Azitra also recorded an impairment expense of $802,800 for intangible assets and deferred patent costs during the nine months, while no comparable expense was recorded in the corresponding period. These items form part of the broader financial picture for the period, alongside higher research and development expenses. Losses and cash use remained prominent themes in the company's results disclosure.
Cash and cash equivalents totaled $3,750,710 on September 30, 2026, compared with $2,068,083 on December 31, 2025. However, the company said cash available at the reporting date would not be sufficient to fund its proposed operating plan for the next twelve months, and that it intends to seek additional financing. The filing said conditions and events raise substantial doubt about the company's ability to continue as a going concern for twelve months from the date the financial statements were available to be issued. The company linked this to the need for significant additional funding to finance development and expected losses. Thus, the increase in cash since the end of 2025 does not remove management's warning about future funding needs.
Azitra said shareholders' equity was about $4.4 million on September 30, below the $6.0 million minimum cited in the filing for NYSE American requirements. The company had said it regained compliance with continued listing standards on August 19, 2026. It added that falling below any of the standards again during the twelve months after that date could prompt a reassessment of its recovery plan or the start of delisting proceedings. This places its listing status among the risks discussed by the company, alongside its financing needs. The filing did not state a subsequent outcome of the compliance review.
Azitra shares closed at $0.6685 in the November 12, 2026 session, according to EL7 data. The closing price was from the session before the news date, and the filing did not attribute the share move to the quarterly results. Liquidity, losses and development expenses, along with listing requirements, remain key elements in assessing the position presented by the company in its report. Management said it would seek additional funding after confirming that available cash would not cover its proposed operating plan for the next twelve months. The filing gave no specific timing for new financing or a subsequent compliance update.